Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial. - Wikidata - wikimedia - TriplyDB

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

http://www.wikidata.org/entity/Q39455228

about

Statin use and breast cancer survival: a nationwide cohort study from Finland Impact of statin use on cancer recurrence and mortality in breast cancer: A systematic review and meta-analysis.Simvastatin, an HMG-CoA reductase inhibitor, exhibits anti-metastatic and anti-tumorigenic effects in endometrial cancer Obesity, cholesterol metabolism, and breast cancer pathogenesis Statins and breast cancer prognosis: evidence and opportunities.Fluvastatin mediated breast cancer cell death: a proteomic approach to identify differentially regulated proteins in MDA-MB-231 cells.Circulating tumor cells in newly diagnosed inflammatory breast cancer.Statin-induced anti-proliferative effects via cyclin D1 and p27 in a window-of-opportunity breast cancer trial.Effects of statin use on volumetric mammographic density: results from the KARMA study.Tumor-specific expression of HMG-CoA reductase in a population-based cohort of breast cancer patients.Modeling cancer metabolism on a genome scale.Statin use and breast cancer survival: a nationwide cohort study in Scotland.Inhibition of NF-κB Pathway and Modulation of MAPK Signaling Pathways in Glioblastoma and Implications for Lovastatin and Tumor Necrosis Factor-Related Apoptosis Inducing Ligand (TRAIL) Combination Therapy.MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1.Genome-wide RNAi analysis reveals that simultaneous inhibition of specific mevalonate pathway genes potentiates tumor cell death.The HMG-CoA reductase inhibitor, simvastatin, exhibits anti-metastatic and anti-tumorigenic effects in ovarian cancer Simvastatin-induced breast cancer cell death and deactivation of PI3K/Akt and MAPK/ERK signalling are reversed by metabolic products of the mevalonate pathway.Targeting tumor cell metabolism via the mevalonate pathway: Two hits are better than one Statin use in primary inflammatory breast cancer: a cohort study.Statin use and all-cancer survival: prospective results from the Women's Health Initiative.Statins and Breast Cancer: Future Directions in Chemoprevention.HMG-CoAR expression in male breast cancer: relationship with hormone receptors, Hippo transducers and survival outcomes.Statins and risk of breast cancer recurrence.LDL-cholesterol signaling induces breast cancer proliferation and invasion.High expression of cholesterol biosynthesis genes is associated with resistance to statin treatment and inferior survival in breast cancer.Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer.HMG-CoA reductase expression in primary colorectal cancer correlates with favourable clinicopathological characteristics and an improved clinical outcome The effect of statins on cancer cells--review.Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs.Prevention and treatment of cancer targeting chronic inflammation: research progress, potential agents, clinical studies and mechanisms.Pre-diagnostic statin use, lymph node status and mortality in women with stages I-III breast cancer.CYP27A1 Loss Dysregulates Cholesterol Homeostasis in Prostate Cancer.The Contribution of Cholesterol and Its Metabolites to the Pathophysiology of Breast Cancer Targeting Cancer Metabolism: Dietary and Pharmacologic Interventions.Protective Effects of Statins in Cancer: Should They Be Prescribed for High-Risk Patients?In vitro studies in a myelogenous leukemia cell line suggest an organized binding of geranylgeranyl diphosphate synthase inhibitors The interplay between cell signalling and the mevalonate pathway in cancer.Statin-induced inhibition of breast cancer proliferation and invasion involves attenuation of iron transport: intermediacy of nitric oxide and antioxidant defence mechanisms.Identifying molecular features that distinguish fluvastatin-sensitive breast tumor cells.Curcumin as a potential candidate for treating hyperlipidemia: A review of cellular and metabolic mechanisms.

P2860

Q28543933-D4560EA6-E555-44E3-A194-EDEE6BD3E233 Q30250324-A9A7B8C2-AE3B-4EC5-97DE-53FCC24BFE40 Q34017200-61B33E4F-4481-40CC-B265-AD5361DBE3C9 Q34204836-2E022AB0-EDF0-40B3-95DD-E8886DD6DB95 Q34206487-3322C751-C866-4F25-BFA3-0F11617F5ACD Q34277789-F6F3C958-EED2-41CB-AD65-770092CCB8F4 Q35052773-3E55B59B-2C58-4CF0-B2CF-69676EBD944A Q35583876-D0F2ECFE-48C0-4621-A476-F7727A352119 Q35643266-5A9C1F07-D442-485E-97AE-930FAB636683 Q35673791-C0D81E52-D575-4E8A-A996-62EC9D9DFED3 Q35850350-5B9167BC-8168-4B01-B7EE-D9CCAEC4A659 Q36095264-A2638FBB-D630-436C-BDE3-2AA4394E2D14 Q36263997-0AC127B9-1CB8-42A3-AF52-ECAB7D0DDB40 Q36343310-643C161A-2E92-459B-84ED-8ADCB3588C63 Q36413650-8D0EF0E4-5882-451B-A388-B13ACCD8E870 Q36729573-7274EDC8-019D-4563-AAD4-32F3A7E88FAE Q36771848-090572B7-F9BB-4E92-9523-C1ACDA7ED5FE Q36997756-A68EE1FE-5F92-40C8-87C3-62CB8D80BF73 Q37040602-2470959D-9C68-44D0-ADE6-7D31185BD9A1 Q37061345-30F7DF35-64EB-4A1A-8201-1C2675B184C0 Q37119810-8BE4941D-E21A-4A11-8EFD-9EF14F1CD3CF Q37319005-7B1C7425-6E70-4401-BF57-C64B442940FA Q37407449-9530E9FD-7A61-43E6-8B25-6E65E61D8E54 Q37497397-B6B3F6EE-47AD-4A81-9BAF-1FCB73478A98 Q37644912-960BBB47-ED31-49CC-9FB6-61AA26F33D41 Q37665580-2A7A9CA6-19D0-4ED5-97C7-CBF88EE0BE92 Q37724074-A0A95EC6-2607-419B-84B4-52E895B9F10F Q38499265-8D44327A-07AA-42F5-B4F4-643612D9C4B6 Q38539671-11C8E9D6-5B92-49E6-91BA-8F78A8209D20 Q38668187-E3758B33-A2D1-4B57-BE3C-C53152F9A9CC Q38673155-D897BE5F-6FFF-4F1D-9625-09992D063BE9 Q38719045-248C187D-5095-411F-A6E7-18D098EF470D Q38791223-703FA582-F536-423E-B2B1-5C69C6D0A385 Q38792334-EA66D1FD-10B9-4771-9299-77B0BCE7F6DE Q38802230-80C7D1BC-CAE7-4CB9-BC01-C754577CAEEC Q38878009-9CC32AD6-75C3-4651-81A0-D50C5BE92512 Q38937455-765F75D3-4898-467F-977D-20357CEE21F9 Q38981350-77D8814E-DA08-44BB-93B5-5571D072076E Q39043383-B07CCBDF-B9E0-4EEA-9748-092077B26179 Q39052351-96B93B33-F1C1-4134-8B33-9F92B7D9075B

P2860

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

http://www.wikidata.org/entity/Q39455228

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@en

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@nl

type

label

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@en

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@nl

prefLabel

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@en

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@nl

P1433

Q39455228-57E15B6D-A081-4C13-A82C-B583F2947A85

P1476

Q39455228-7028D026-A454-40A1-AE5A-239C72A9ECF8

P2093

Q39455228-4B2345F7-136C-4FC7-A3C2-3BC4DBE272B7

Q39455228-728F0E3C-D0A6-4926-B848-891C099F4780

Q39455228-8D9CE9DF-BA23-484B-8C6C-AE44D99A365F

Q39455228-9F3140D2-872B-4DEA-9CC9-D947CEAA50CA

Q39455228-A116E167-3C3B-4B27-B039-40043B880327

Q39455228-BDF12886-0A0D-417A-9371-54B44AE42DBA

Q39455228-EF38A590-BCB8-4321-881C-B24AFCC66351

Q39455228-F6AA3E3B-DCF3-46B9-A48B-EA70A9072489

P2860

Q39455228-056EE454-2EB2-4543-B43E-B45DBEE867FF

Q39455228-0CBE38D7-F7B1-4600-A1A2-384F7E2A10EA

Q39455228-13600230-673E-4D9E-B6F2-1092209D3C1B

Q39455228-24B61C1F-2528-4B25-BA47-271B10AD0EB0

Q39455228-27F5ECE2-2944-4411-A3B9-5BD4DEEB055A

Q39455228-283503BA-89BF-464C-A31D-508D7AAE6E05

Q39455228-2EDAF679-3B05-4B9F-B26C-7A0B2DDDBA08

Q39455228-32FD9F9D-5B6B-48BF-8587-E33BFE738B14

Q39455228-3C247A62-1D91-4554-A71F-5FB15B7C89C3

Q39455228-417B8F73-790B-4617-86D4-E65CF536B330

P2888

Q39455228-B79EBB6C-9DBA-4708-AB4B-65C7F1F4F688

P304

Q39455228-AF41985D-5586-4C1C-BED2-9B9E2509A9CC

P31

Q39455228-916A6B9F-4063-4E2B-86C4-0B4EC716E940

P356

Q39455228-81090159-52A7-46CB-A7FA-856A9943E0E3

P407

Q39455228-689FC175-AD14-439D-9E4C-0D17F6CA2CDE

P433

Q39455228-00C11367-73CC-425B-81E9-70DE038036C0

P478

Q39455228-D5ACF9D1-C883-43E3-99EB-4BAB3452944D

P50

Q39455228-1C2F028C-A3AD-4ECF-BD9D-1329E9C1EBB2

Q39455228-65C34525-30C2-48CC-977D-BCCD9F203D38

Q39455228-6761BF1E-5A8E-4934-BEE4-11E53B1D5B37

P577

Q39455228-D550F0E6-5AB8-497C-A01A-31DAF5C4EFAD

P5875

Q39455228-AE62D601-1A05-4B59-A962-E34B21BA1501

P698

Q39455228-FCEB282D-4BCF-4DEA-BEFA-2177946F0E9A

P356

S10549-013-2473-6

P1433

Breast Cancer Research and Treatment

P1476

Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.

@en

P2093

Carsten Rose

http://www.w3.org/2001/XMLSchema#string

Dorthe Grabau

http://www.w3.org/2001/XMLSchema#string

Henrik Johannesson

http://www.w3.org/2001/XMLSchema#string

Lisa Rydén

http://www.w3.org/2001/XMLSchema#string

Niklas Loman

http://www.w3.org/2001/XMLSchema#string

Olöf Bjarnadottir

http://www.w3.org/2001/XMLSchema#string

Pär-Ola Bendahl

http://www.w3.org/2001/XMLSchema#string

Quinci Romero

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular mechanisms involved in farnesol-induced apoptosis

Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy

Regulation of the mevalonate pathway

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

Fluvastatin reduces proliferation and increases apoptosis in women with high grade breast cancer.

Ki67 proliferation in core biopsies versus surgical samples - a model for neo-adjuvant breast cancer studies.

Dysregulation of the mevalonate pathway promotes transformation

Novel aspects of mevalonate pathway inhibitors as antitumor agents.

Statin use and risk of breast cancer: a meta-analysis of observational studies.

P2888

s10549-013-2473-6

P304

499-508

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10549-013-2473-6

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

138

http://www.w3.org/2001/XMLSchema#string

P50

Karin Jirström

Signe Borgquist

P577

2013-03-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

235885955

http://www.w3.org/2001/XMLSchema#string

P698

23471651

http://www.w3.org/2001/XMLSchema#string